Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 10/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.54 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12189542 | 1.00 | FAAH (0.56) | FAAHGAAL3MBTL1S1PR1S1PR3 | |
| SCHEMBL12835024 | 1.00 | FAAH (0.56) | FAAHGAAL3MBTL1S1PR1S1PR3 | |
| SCHEMBL7825824 | 0.86 | TAS1R3 (0.61) | GAATP53HTT | |
| SCHEMBL12835062 | 0.85 | FAAH (0.50) | FAAHGAAL3MBTL1S1PR1S1PR3 | |
| SCHEMBL12189646 | 0.84 | PTPN1 (0.51) | HTT | |
| SCHEMBL12189414 | 0.84 | PTPN1 (0.56) | GAAS1PR1S1PR3NR1H4 | |
| SCHEMBL12835495 | 0.83 | FAAH (0.56) | FAAHGAAL3MBTL1S1PR1S1PR3 | |
| SCHEMBL12189554 | 0.83 | FAAH (0.56) | FAAHGAAL3MBTL1S1PR1S1PR3 | |
| SCHEMBL12189643 | 0.83 | FAAH (0.56) | FAAHGAAL3MBTL1S1PR1S1PR3 | |
| SCHEMBL12189645 | 0.83 | FAAH (0.56) | FAAHGAAL3MBTL1S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232150-A1 | PHTHALANILATE COMPOUNDS AND METHODS OF USE | University of Nortre Dame du Lac | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232150-A1 | PHTHALANILATE COMPOUNDS AND METHODS OF USE | MPO, ALPI, NQO1 | FAAH 2194/4885GAA 84/4885L3MBTL1 3370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.